Covidien plc (NYSE: COV) issued its quarterly earnings data on Friday. The company reported $1.10 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.06 by $0.04. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.00 billion. During the same quarter in the prior year, the company posted $1.13 earnings per share. The company?s quarterly revenue was up 5.5% on a year-over-year basis.
A number of research firms have also recently commented on COV. Analysts at TheStreet reiterated a ?buy? rating on shares of Covidien plc in a research note to investors on Tuesday, January 8th. On the ratings front, analysts at Deutsche Bank raised their price target on shares of Covidien plc from $64.00 to $70.00 in a research note to investors on Friday, January 4th. They now have a ?buy? rating on the stock. Finally, analysts at Citigroup reiterated a ?buy? rating on shares of Covidien plc in a research note to investors on Wednesday, January 2nd. They now have a $64.00 price target on the stock.
Eighteen investment analysts have rated the stock with a buy rating, and three have given a hold rating to the company?s stock. Covidien plc presently has a consensus rating of ?buy? and an average target price of $65.19.
Shares of Covidien plc (COV) opened at 61.67 on Friday. Covidien plc (COV) has a one year low of $50.25 and a one year high of $61.69. The stock?s 50-day moving average is currently $58.76. The company has a market cap of $29.194 billion and a P/E ratio of 15.71.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.